Michael Colacci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael Colacci has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Ayodele Odutayo
Department of Medicine, General Internal Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, General Internal Medicine, University of Calgary, Calgary, Alberta, Canada
3 shared publications- Michael Fralick
Department of Medicine University of Toronto Toronto Ontario Canada
3 shared publications - Amol A. Verma
Department of Medicine, University of Toronto, Toronto, Ontario, Canada
2 shared publications Fahad Razak
Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada
2 shared publicationsJohn Fralick
Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsMichael Fralick
Department of Medicine, Sinai Health System and the University of Toronto, Toronto, Ontario, Canada; Department of Medicine, General Internal Medicine, University of Toronto, Toronto, Ontario, Canada
2 shared publications
Latest Publications
- 17 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e275025
Haemolytic anaemia and thrombocytopenia following phenobarbital therapy for alcohol withdrawal
Drug-induced immune haemolytic anaemia (DIIHA) is a rare but potentially life-threatening condition. Phenobarbital is increasingly used for the management of alcohol withdrawal; however, haematologic toxicity is infrequently reported. We describe a man in his 50s admitted for alcohol withdrawal who developed acute anaemia and thrombocytopenia shortly after initiation of phenobarbital. Laboratory findings were consistent with haemolysis, including undetectable haptoglobin and indirect hyperbilirubinaemia, although the direct antiglobulin test was negative. Alternative causes were excluded. Following discontinuation of phenobarbital, haematologic parameters improved rapidly. This case highlights a probable instance of phenobarbital-associated haemolysis with thrombocytopenia and emphasises the importance of recognising DIIHA even in the absence of a positive antiglobulin test.
- 17 September 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e275025
Haemolytic anaemia and thrombocytopenia following phenobarbital therapy for alcohol withdrawal
Drug-induced immune haemolytic anaemia (DIIHA) is a rare but potentially life-threatening condition. Phenobarbital is increasingly used for the management of alcohol withdrawal; however, haematologic toxicity is infrequently reported. We describe a man in his 50s admitted for alcohol withdrawal who developed acute anaemia and thrombocytopenia shortly after initiation of phenobarbital. Laboratory findings were consistent with haemolysis, including undetectable haptoglobin and indirect hyperbilirubinaemia, although the direct antiglobulin test was negative. Alternative causes were excluded. Following discontinuation of phenobarbital, haematologic parameters improved rapidly. This case highlights a probable instance of phenobarbital-associated haemolysis with thrombocytopenia and emphasises the importance of recognising DIIHA even in the absence of a positive antiglobulin test.
- Open Access
- 3 November 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (6)
Evaluating sociodemographic bias in a deployed machine-learned patient deterioration model
Background: Bias evaluations of machine learning (ML) models often focus on performance in research settings, with limited assessment of downstream bias following clinical deployment. The objective of this study was to evaluate whether CHARTwatch, a real-time ML early warning system for inpatient deterioration, demonstrated algorithmic bias in model performance, or produced disparities in care processes, and outcomes across patient sociodemographic groups. Methods: We evaluated CHARTwatch implementation on the internal medicine service at a large academic hospital. Patient outcomes during the intervention period (November 1, 2020–June 1, 2022) were compared to the control period (November 1, 2016–December 31, 2019) using propensity score overlap weighting. We evaluated differences across key sociodemographic subgroups, including age, sex, homelessness, and neighborhood-level socioeconomic and racialized composition. Outcomes included model performance (sensitivity and specificity), processes of care, and patient outcomes (non-palliative in-hospital death). Results: Among 12 877 patients (9079 control, 3798 intervention), 13.3% were experiencing homelessness and 36.9% lived in the quintile with the highest neighborhood racialized and newcomer populations. Model sensitivity was 70.1% overall, with no significant variation across subgroups. Model specificity varied by age, 80 years: 84% (95%CI 79-88%), P < .001, but not other subgroups. CHARTwatch implementation was associated with an increase in code status documentation among patients experiencing homelessness, without significant differences in other care processes or outcomes. Conclusion: CHARTwatch model performance and impact were generally consistent across measured sociodemographic subgroups. ML-based clinical decision support tools, and associated standardization of care, may reduce existing inequities, as was observed for code status orders among patients experiencing homelessness. This evaluation provides a framework for future bias assessments of deployed ML-CDS tools.
- 3 November 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (6)
Open AccessEvaluating sociodemographic bias in a deployed machine-learned patient deterioration model
Background: Bias evaluations of machine learning (ML) models often focus on performance in research settings, with limited assessment of downstream bias following clinical deployment. The objective of this study was to evaluate whether CHARTwatch, a real-time ML early warning system for inpatient deterioration, demonstrated algorithmic bias in model performance, or produced disparities in care processes, and outcomes across patient sociodemographic groups. Methods: We evaluated CHARTwatch implementation on the internal medicine service at a large academic hospital. Patient outcomes during the intervention period (November 1, 2020–June 1, 2022) were compared to the control period (November 1, 2016–December 31, 2019) using propensity score overlap weighting. We evaluated differences across key sociodemographic subgroups, including age, sex, homelessness, and neighborhood-level socioeconomic and racialized composition. Outcomes included model performance (sensitivity and specificity), processes of care, and patient outcomes (non-palliative in-hospital death). Results: Among 12 877 patients (9079 control, 3798 intervention), 13.3% were experiencing homelessness and 36.9% lived in the quintile with the highest neighborhood racialized and newcomer populations. Model sensitivity was 70.1% overall, with no significant variation across subgroups. Model specificity varied by age, 80 years: 84% (95%CI 79-88%), P < .001, but not other subgroups. CHARTwatch implementation was associated with an increase in code status documentation among patients experiencing homelessness, without significant differences in other care processes or outcomes. Conclusion: CHARTwatch model performance and impact were generally consistent across measured sociodemographic subgroups. ML-based clinical decision support tools, and associated standardization of care, may reduce existing inequities, as was observed for code status orders among patients experiencing homelessness. This evaluation provides a framework for future bias assessments of deployed ML-CDS tools.
- Open Access
- 2 January 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (1) , e2454745
Patient Complexity, Social Factors, and Hospitalization Outcomes at Academic and Community Hospitals
Importance: There have been limited evaluations of the patients treated at academic and community hospitals. Understanding differences between academic and community hospitals has relevance for the design of clinical models of care, remuneration for clinical services, and health professional training programs.Objective: To evaluate differences in complexity and clinical outcomes between patients admitted to general medical wards at academic and community hospitals.Design, Setting, and Participants: This retrospective cohort study of patients admitted to general medicine at 28 hospitals in Ontario, Canada, was conducted between April 2015 and December 2021. All patients admitted to or discharged from general medicine during the study period who were older than 18 years were included. Data analysis occurred between February 2023 and June 2024.Exposures: Patient admission to a general medicine inpatient service at an academic or community hospital.Main Outcomes and Measures: Demographic and clinical characteristics (age, sex, modified Laboratory-based Acute Physiology Score [mLAPS], discharge diagnosis, Charlson Comorbidity Index, frailty risk score, and disability), social factors (neighborhood-level markers of income, material deprivation, immigrant status, and racial and ethnic minority status) and clinical outcomes and processes (patient volume per physician, in-hospital mortality, length of stay, readmission rates, and intensive care unit [ICU] admission rates).Results: There were 947 070 admissions, including 609 696 at 17 community hospitals (median [IQR] age, 73 [58-84] years) and 337 374 at 11 academic hospitals (median [IQR] age, 70 [56-82] years). Baseline clinical characteristics were similar at community and academic hospitals, including female sex (307 381 [50.4%] vs 168 033 [49.8%]; standardized mean difference [SMD] = 0.012), median (IQR) mLAPS (21 [11-36] vs 21 [10-34]; SMD = 0.001), and Charlson Comorbidity Index score of 2 or greater (182 171 [29.9%] vs 105 502 [31.3%]; SMD = 0.038). Social characteristics, including income, education, and neighborhood proportion of racial and ethnic minority and immigrant residents were also similar. The number of unique discharge diagnoses was similar at academic and community hospitals. Patient volumes per attending physician were higher at academic hospitals (median [IQR] daily census, 20 [19-22] vs 17 [15-19]; SMD = 1.086). After multivariable regression adjusting for baseline factors, mortality (adjusted odds ratio [aOR], 0.96; 95% CI, 0.78 to 1.17), ICU admission rate (aOR, 1.20; 95% CI, 0.80 to 1.79) and length of stay (β = −0.001; 95% CI, −0.10 to 0.10) were not significantly different, while 7-day readmission (aOR, 1.25; 95% CI, 1.10 to 1.43) and 30-day readmission (aOR, 1.25; 95% CI, 1.10 to 1.42) were significantly higher at academic hospitals than community hospitals.Conclusions and Relevance: In this cohort study, patients admitted to general medicine at academic and community hospitals had similar baseline clinical characteristics and generally similar clinical outcomes, with greater readmission rates in academic hospitals. These findings suggest that the patient case mix in general internal medicine that trainees would be exposed to during their residency training at academic hospitals is largely representative of the case mix they would encounter at community hospitals, and has important implications for health services planning and funding.
- 2 January 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (1) , e2454745
Open AccessPatient Complexity, Social Factors, and Hospitalization Outcomes at Academic and Community Hospitals
Importance: There have been limited evaluations of the patients treated at academic and community hospitals. Understanding differences between academic and community hospitals has relevance for the design of clinical models of care, remuneration for clinical services, and health professional training programs.Objective: To evaluate differences in complexity and clinical outcomes between patients admitted to general medical wards at academic and community hospitals.Design, Setting, and Participants: This retrospective cohort study of patients admitted to general medicine at 28 hospitals in Ontario, Canada, was conducted between April 2015 and December 2021. All patients admitted to or discharged from general medicine during the study period who were older than 18 years were included. Data analysis occurred between February 2023 and June 2024.Exposures: Patient admission to a general medicine inpatient service at an academic or community hospital.Main Outcomes and Measures: Demographic and clinical characteristics (age, sex, modified Laboratory-based Acute Physiology Score [mLAPS], discharge diagnosis, Charlson Comorbidity Index, frailty risk score, and disability), social factors (neighborhood-level markers of income, material deprivation, immigrant status, and racial and ethnic minority status) and clinical outcomes and processes (patient volume per physician, in-hospital mortality, length of stay, readmission rates, and intensive care unit [ICU] admission rates).Results: There were 947 070 admissions, including 609 696 at 17 community hospitals (median [IQR] age, 73 [58-84] years) and 337 374 at 11 academic hospitals (median [IQR] age, 70 [56-82] years). Baseline clinical characteristics were similar at community and academic hospitals, including female sex (307 381 [50.4%] vs 168 033 [49.8%]; standardized mean difference [SMD] = 0.012), median (IQR) mLAPS (21 [11-36] vs 21 [10-34]; SMD = 0.001), and Charlson Comorbidity Index score of 2 or greater (182 171 [29.9%] vs 105 502 [31.3%]; SMD = 0.038). Social characteristics, including income, education, and neighborhood proportion of racial and ethnic minority and immigrant residents were also similar. The number of unique discharge diagnoses was similar at academic and community hospitals. Patient volumes per attending physician were higher at academic hospitals (median [IQR] daily census, 20 [19-22] vs 17 [15-19]; SMD = 1.086). After multivariable regression adjusting for baseline factors, mortality (adjusted odds ratio [aOR], 0.96; 95% CI, 0.78 to 1.17), ICU admission rate (aOR, 1.20; 95% CI, 0.80 to 1.79) and length of stay (β = −0.001; 95% CI, −0.10 to 0.10) were not significantly different, while 7-day readmission (aOR, 1.25; 95% CI, 1.10 to 1.43) and 30-day readmission (aOR, 1.25; 95% CI, 1.10 to 1.42) were significantly higher at academic hospitals than community hospitals.Conclusions and Relevance: In this cohort study, patients admitted to general medicine at academic and community hospitals had similar baseline clinical characteristics and generally similar clinical outcomes, with greater readmission rates in academic hospitals. These findings suggest that the patient case mix in general internal medicine that trainees would be exposed to during their residency training at academic hospitals is largely representative of the case mix they would encounter at community hospitals, and has important implications for health services planning and funding.
- Open Access
- 10 November 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 178, 111606
Sociodemographic bias in clinical machine learning models: a scoping review of algorithmic bias instances and mechanisms
- 10 November 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 178, 111606
Open AccessSociodemographic bias in clinical machine learning models: a scoping review of algorithmic bias instances and mechanisms
- Open Access
- 29 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0307581
Demographics, medication use, and admission characteristics of patients hospitalized with diabetes in Ontario, Canada: A retrospective cohort study
Background: In Canada, one in seven adults has diabetes (i.e., 2.3 million) and the lifetime risk of developing diabetes is approximately 30% by age 65. Although 30% of patients admitted to the hospital have diabetes, data from inpatient hospitalizations for patients with diabetes are lacking, both in Canada and globally. Objective: To validate International Classification of Diseases 10th edition Canadian version (ICD-10-CA) codes for the identification of patients with diabetes, to create a multicenter database of patients with diabetes hospitalized under internal medicine in Ontario, and to determine their baseline characteristics, medication use, and admission characteristics. Study design: We created a database of people who had diabetes and were hospitalized between 2010 and 2020 at 8 hospitals in Ontario that were part of the General Medicine Inpatient Initiative (GEMINI) hospital data-sharing network. Patients who had diabetes were identified using chart review, based upon either (i) a previous physician diagnosis of diabetes, (ii) a recorded hemoglobin A1c ≥ 6.5% or (iii) outpatient prescription of a diabetes medication preceding the hospitalization. The test characteristics of ICD-10-CA codes for diabetes were evaluated. We compared baseline demographics, medication use and hospitalization details among patients with and without diabetes. For hospitalization details, we collected information on the admission diagnosis, comorbidity index, length of stay, receipt of ICU-level care, and inpatient mortality. Results: There were 384,588 admissions within the total study cohort, of which 118,987 (30.9%) had an ICD-10-CA diagnosis code of diabetes (E10.x, E11.x, E13.x, E14.x). The sensitivity and specificity of ICD-10-CA diagnostic codes was 95.9% and 98.8%, respectively. Most patients with an ICD-10-CA code for diabetes had a code for type 2 diabetes (93.9%) and a code for type 1 diabetes was rare (6.1%). The mean age was 66.4 years for patients without diabetes and 71.3 years for those with an ICD-10-CA diagnosis code for diabetes. Patients with diabetes had a higher prevalence of hypertension (64% vs. 37.9%), coronary artery disease (28.7% vs. 15.3%), heart failure (24.5% vs. 12.1%) and renal failure (33.8% vs. 17.3%) in comparison to those without diabetes. The most prevalent diabetes medications received in hospital were metformin (43%), DPP4 inhibitors (22.7%) and sulfonylureas (18.8%). The most common reason for admission among patients with diabetes was heart failure (9.0%), and among patients without diabetes was pneumonia (7.8%). Median length of stay was longer for patients with diabetes (5.5 vs. 4.5 days) and in-hospital mortality was similar between groups (6.8% with diabetes vs. 6.5% without diabetes). Importance: Diabetes is one of the most prevalent chronic medical conditions, affecting roughly one third of all patients hospitalized on an internal medicine ward and is associated with other comorbidities and longer hospital stays. ICD-10-CA codes were highly accurate in identifying patients with diabetes. The development of an inpatient cohort will allow for further study of in-hospital practices and outcomes among patients with diabetes.
- 29 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0307581
Open AccessDemographics, medication use, and admission characteristics of patients hospitalized with diabetes in Ontario, Canada: A retrospective cohort study
Background: In Canada, one in seven adults has diabetes (i.e., 2.3 million) and the lifetime risk of developing diabetes is approximately 30% by age 65. Although 30% of patients admitted to the hospital have diabetes, data from inpatient hospitalizations for patients with diabetes are lacking, both in Canada and globally. Objective: To validate International Classification of Diseases 10th edition Canadian version (ICD-10-CA) codes for the identification of patients with diabetes, to create a multicenter database of patients with diabetes hospitalized under internal medicine in Ontario, and to determine their baseline characteristics, medication use, and admission characteristics. Study design: We created a database of people who had diabetes and were hospitalized between 2010 and 2020 at 8 hospitals in Ontario that were part of the General Medicine Inpatient Initiative (GEMINI) hospital data-sharing network. Patients who had diabetes were identified using chart review, based upon either (i) a previous physician diagnosis of diabetes, (ii) a recorded hemoglobin A1c ≥ 6.5% or (iii) outpatient prescription of a diabetes medication preceding the hospitalization. The test characteristics of ICD-10-CA codes for diabetes were evaluated. We compared baseline demographics, medication use and hospitalization details among patients with and without diabetes. For hospitalization details, we collected information on the admission diagnosis, comorbidity index, length of stay, receipt of ICU-level care, and inpatient mortality. Results: There were 384,588 admissions within the total study cohort, of which 118,987 (30.9%) had an ICD-10-CA diagnosis code of diabetes (E10.x, E11.x, E13.x, E14.x). The sensitivity and specificity of ICD-10-CA diagnostic codes was 95.9% and 98.8%, respectively. Most patients with an ICD-10-CA code for diabetes had a code for type 2 diabetes (93.9%) and a code for type 1 diabetes was rare (6.1%). The mean age was 66.4 years for patients without diabetes and 71.3 years for those with an ICD-10-CA diagnosis code for diabetes. Patients with diabetes had a higher prevalence of hypertension (64% vs. 37.9%), coronary artery disease (28.7% vs. 15.3%), heart failure (24.5% vs. 12.1%) and renal failure (33.8% vs. 17.3%) in comparison to those without diabetes. The most prevalent diabetes medications received in hospital were metformin (43%), DPP4 inhibitors (22.7%) and sulfonylureas (18.8%). The most common reason for admission among patients with diabetes was heart failure (9.0%), and among patients without diabetes was pneumonia (7.8%). Median length of stay was longer for patients with diabetes (5.5 vs. 4.5 days) and in-hospital mortality was similar between groups (6.8% with diabetes vs. 6.5% without diabetes). Importance: Diabetes is one of the most prevalent chronic medical conditions, affecting roughly one third of all patients hospitalized on an internal medicine ward and is associated with other comorbidities and longer hospital stays. ICD-10-CA codes were highly accurate in identifying patients with diabetes. The development of an inpatient cohort will allow for further study of in-hospital practices and outcomes among patients with diabetes.
- Open Access
- 19 July 2023
- Published by Wiley in Journal of Hospital Medicine
- Vol. 18 (11) , 1017-1020
Methodological progress note: Utilizing inpatient data sources to minimize common biases when emulating target trials
- 19 July 2023
- Published by Wiley in Journal of Hospital Medicine
- Vol. 18 (11) , 1017-1020
Open AccessMethodological progress note: Utilizing inpatient data sources to minimize common biases when emulating target trials
- 1 February 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (1) , 10-15.e2
Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis
- 1 February 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (1) , 10-15.e2
Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis
- Open Access
SGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with Type 2 Diabetes: A systematic review and meta-analysis
Importance The risk of diabetic ketoacidosis (DKA) with sodium-glucose cotransporter-2 (SGLT2) inhibitors is unclear. Objective To examine the risk of DKA with SGLT2 inhibitors in both observational studies and large clinical trials. Data Sources Searches of PubMed, EMBASE and CENTRAL (inception to 15 April 2019) without language restrictions; conference proceedings; and reference lists. Study Selection Randomized controlled trials and observational studies that quantified the rate of diabetic ketoacidosis with an SGLT2 inhibitor in comparison to another diabetes medication or placebo. Data Extraction and Synthesis Two independent investigators abstracted study data and assessed the quality of evidence. Data were pooled using random effects models with the Hartung-Knapp-Sidik-Jonkman method. Main Outcome and Measures Absolute event rates and hazard ratios for diabetic ketoacidosis were extracted from each study. Results Seven randomized trials encompassing 42,375 participants and five cohort studies encompassing 318,636 participants were selected. Among the 7 randomized controlled trials, the absolute rate of DKA among patients randomized to an SGLT2 inhibitor ranged from 0.6 to 2.2 events per 1000 person years. Four randomized trials were included in the meta-analysis, and compared to placebo or comparator medication, SGLT2 inhibitors had a 2.4-fold higher risk of DKA (Relative Risk⍰[RR] =⍰2.46 [95% CI, 1.16-5.21]; I2⍰=⍰0%; P⍰= 0.54). Among the 5 observational studies, the absolute rate of DKA associated with SGLT2 inhibitor use ranged from 0.6 to 4.9 per 1000 person years and a 1.7-fold higher rate of DKA compared to another diabetes medication (RR⍰=⍰1.74 [95% CI, 1.01-2.93]; I2⍰=⍰45%; P⍰= 0.12). Conclusions and Relevance In adults with type 2 diabetes, SGLT2 inhibitors increase the risk of DKA in both observational studies and large randomized clinical trials. Registration CRD42019146855 Funding Source None KEY MESSAGES ‐ Case reports and observational studies have suggested that SGLT2 inhibitors may be associated with an increased risk of DKA, but this finding has not been reproduced in older meta-analyses of randomized controlled trials. ‐ In this systematic review and meta-analysis of randomized trials and observational studies including over 350,000 patients, SGLT2 inhibitors were found to be associated with twice the risk of diabetic ketoacidosis versus placebo or a comparator medication. ‐ Patients receiving an SGLT2 inhibitors should be counselled on this risk and provided with appropriate sick-day medication management.
Open AccessSGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with Type 2 Diabetes: A systematic review and meta-analysis
Importance The risk of diabetic ketoacidosis (DKA) with sodium-glucose cotransporter-2 (SGLT2) inhibitors is unclear. Objective To examine the risk of DKA with SGLT2 inhibitors in both observational studies and large clinical trials. Data Sources Searches of PubMed, EMBASE and CENTRAL (inception to 15 April 2019) without language restrictions; conference proceedings; and reference lists. Study Selection Randomized controlled trials and observational studies that quantified the rate of diabetic ketoacidosis with an SGLT2 inhibitor in comparison to another diabetes medication or placebo. Data Extraction and Synthesis Two independent investigators abstracted study data and assessed the quality of evidence. Data were pooled using random effects models with the Hartung-Knapp-Sidik-Jonkman method. Main Outcome and Measures Absolute event rates and hazard ratios for diabetic ketoacidosis were extracted from each study. Results Seven randomized trials encompassing 42,375 participants and five cohort studies encompassing 318,636 participants were selected. Among the 7 randomized controlled trials, the absolute rate of DKA among patients randomized to an SGLT2 inhibitor ranged from 0.6 to 2.2 events per 1000 person years. Four randomized trials were included in the meta-analysis, and compared to placebo or comparator medication, SGLT2 inhibitors had a 2.4-fold higher risk of DKA (Relative Risk⍰[RR] =⍰2.46 [95% CI, 1.16-5.21]; I2⍰=⍰0%; P⍰= 0.54). Among the 5 observational studies, the absolute rate of DKA associated with SGLT2 inhibitor use ranged from 0.6 to 4.9 per 1000 person years and a 1.7-fold higher rate of DKA compared to another diabetes medication (RR⍰=⍰1.74 [95% CI, 1.01-2.93]; I2⍰=⍰45%; P⍰= 0.12). Conclusions and Relevance In adults with type 2 diabetes, SGLT2 inhibitors increase the risk of DKA in both observational studies and large randomized clinical trials. Registration CRD42019146855 Funding Source None KEY MESSAGES ‐ Case reports and observational studies have suggested that SGLT2 inhibitors may be associated with an increased risk of DKA, but this finding has not been reproduced in older meta-analyses of randomized controlled trials. ‐ In this systematic review and meta-analysis of randomized trials and observational studies including over 350,000 patients, SGLT2 inhibitors were found to be associated with twice the risk of diabetic ketoacidosis versus placebo or a comparator medication. ‐ Patients receiving an SGLT2 inhibitors should be counselled on this risk and provided with appropriate sick-day medication management.
- 1 November 2020
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 34 (11) , 107704
Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis
- 1 November 2020
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 34 (11) , 107704
Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis